Table 1 Baseline patient characteristics.

From: Risk prediction of multiple-station N2 metastasis in patients with upfront surgery for clinical single-station N2 non-small cell lung cancer

Variables

Total

(N = 547)

N2a (N = 242)

N2b (N = 129)

p value

Age

63.1 ± 9.5

62.7 ± 8.8

61.0 ± 11.6

0.132

  ≤ 50 year

62 (11.3%)

23 (9.5%)

30 (23.3%)

0.001

  > 50 year

485 (88.7%)

219 (90.5%)

99 (76.7%)

Sex

 F

113 (20.7%)

51 (21.1%)

37 (28.7%)

0.13

 M

434 (79.3%)

191 (78.9%)

92 (71.3%)

The number of Comorbidity

 0

261 (47.7%)

122 (50.4%)

67 (51.9%)

0.452

 1

174 (31.8%)

68 (28.1%)

41 (31.8%)

 2

112 (20.5%)

52 (21.5%)

21 (16.3%)

FEV1

84.7 ± 15.7

85.8 ± 16.0

86.7 ± 14.5

0.626

DLCO

81.8 ± 17.1

82.3 ± 17.5

83.7 ± 14.7

0.412

Smoking

 No

111 (20.9%)

40 (17.8%)

42 (32.6%)

0.002

 Yes

419 (79.1%)

185 (82.2%)

87 (67.4%)

Histology

 Adenocarcinoma

242 (44.2%)

109 (45.0%)

94 (72.9%)

 < 0.001

 SqCC

261 (47.7%)

112 (46.3%)

26 (20.2%)

 Others

44 (8.0%)

21 (8.7%)

9 (7.0%)

N2 LN biopsy

 Yes

159 (29.1%)

73 (30.2%)

53 (41.1%)

0.045

 No

388 (70.9%)

169 (69.8%)

76 (58.9%)

Mediastinal LN evaluation

 EBUS

128 (23.4%)

57 (23.6%)

41 (31.8%)

0.113

 EUS

2 (0.4%)

0 (0%)

1 ( 0.8%)

 Mediastinoscope

29 (5.3%)

16 (6.6%)

11 ( 8.5%)

 None

388 (70.9%)

169 (69.8%)

76 (58.9%)

PreOP confirmed N2

 Yes

125 (22.9%)

68 (28.1%)

53 (41.1%)

0.015

 No

422(77.1%)

174 (71.9%)

76 (58.9%)

Cancer size (PreOP)

42.4 ± 20.9

39.9 ± 17.8

40.4 ± 21.2

0.831

Clinical T staging

 T1

122 (22.3%)

63 (26.0%)

31 (24%)

0.017

 T2

239 (43.7%)

96 (39.7%)

42 (32.6%)

 T3

123 (22.5%)

55 (22.7%)

48 (37.2%)

 T4

63 (11.5%)

28 (11.6%)

8 (6.2%)

Clinical staging

 IIIA

361 (66.0%)

159 (65.7%)

73 (56.6%)

0.106

 IIIB

186 (34.0%)

83 (34.3%)

56 (43.4%)

OP type

0.366

 Open

397 (72.6%)

174 (71.9%)

89 (69.0%)

 VATS

150 (27.4%)

68 (28.1%)

40 (31.0%)

OP extent

1

 Segmentectomy

4 (0.7%)

2 (0.8%)

1 (0.8%)

 Lobectomy

405 (74.0%)

183 (75.6%

103 (79.8%)

 Bilobectomy

65 (11.9%)

26 (10.7%)

14 (10.9%)

 Pneumonectomy

45 (8.2%)

19 (7.9%)

8 (6.2%)

 Sleeve lobectomy

28 (5.1%)

12 (5.0%)

3 (2.3%)

Resection margin

1

 R0

478 (87.4%)

207 (85.5%)

115 (89.1%)

 R1

61 (11.2%)

29 (12.0%)

12 (9.3%)

 R2

8 (1.5%)

6 (2.5%)

2 (1.6%)

Cancer size (PostOP)

44.6 ± 21.8

43.0 ± 20.7

42.2 ± 21.1

0.016

Pathologic T staging

1

 T1

93 (17.0%)

37 (15.3%)

25 (19.4%)

 T2

243 (44.4%)

118 (48.8%)

61 (47.3%)

 T3

130 (23.8%)

52 (21.5%)

30 (23.3%)

 T4

81 (14.8%)

35 (14.5%)

13 (10.1%)

Pathologic M staging

1

 M0

541 (98.9%)

237 (97.9%)

129 (100%)

 M1a

6 (1.1%)

5 (2.1%)

0 (0.0%)

  1. DLCO Diffusing capacity of the lungs for carbon monoxide; EBUS Endobronchial ultrasound scan; EUS Endoscopic ultrasound scan; FEV1 Forced expiratory volume; SqCC Squamous cell carcinoma; VATS Video-assisted thoracoscopic surgery.